Waldman Silvina V, Blumenthal James A, Babyak Michael A, Sherwood Andrew, Sketch Michael, Davidson Jonathan, Watkins Lana L
Duke University Medical Center, Durham, NC 27710, USA.
Am Heart J. 2009 Jan;157(1):77-83. doi: 10.1016/j.ahj.2008.08.013. Epub 2008 Oct 21.
The aim of this study is to examine ethnic differences in depressive symptoms and antidepressant treatment in a cohort of patients undergoing diagnostic coronary angiography.
Coronary heart disease (CHD) is the leading cause of mortality in the United States, with an excess of mortality in African Americans. Traditional risk factors occur more frequently among African Americans but do not fully account for this increased risk. Elevated depressive symptoms have been shown to be associated with higher morbidity and mortality in patients with CHD.
A consecutive series of 864 patients (727 whites, 137 African Americans) completed the Beck Depression Inventory to assess depressive symptoms. Data describing cardiovascular risk factors and type of medications including antidepressants were obtained from chart review at the time of study enrollment.
There was no difference in the severity of depressive symptoms between whites (P = .50); the prevalence of elevated depressive symptoms also was similar for African Americans (35%) and whites (27%) (P = .20). However, the rate of antidepressant use was 21% for whites but only 11.7% for African Americans (P = .016). The odds ratio for ethnicity (African American vs whites) in predicting antidepressant use was 0.43 (95% confidence interval 0.24-0.76, P = .004) after adjustment for Beck Depression Inventory scores.
African Americans with CHD are less likely to be treated with antidepressant medications compared with whites despite having similar levels of depression. The ethnic differences in the psychopharmacological management of depression suggests that more careful assessment of depression, especially in African Americans, is necessary to optimize care of patients with CHD.
本研究旨在探讨接受诊断性冠状动脉造影的患者队列中抑郁症状和抗抑郁治疗的种族差异。
冠心病(CHD)是美国的主要死因,非裔美国人的死亡率更高。传统危险因素在非裔美国人中更频繁出现,但不能完全解释这种增加的风险。抑郁症状升高已被证明与冠心病患者的更高发病率和死亡率相关。
连续纳入864例患者(727例白人,137例非裔美国人),完成贝克抑郁量表以评估抑郁症状。在研究入组时,通过病历审查获得描述心血管危险因素和包括抗抑郁药在内的药物类型的数据。
白人之间抑郁症状的严重程度无差异(P = 0.50);非裔美国人(35%)和白人(27%)抑郁症状升高的患病率也相似(P = 0.20)。然而,白人使用抗抑郁药的比例为21%,而非裔美国人仅为11.7%(P = 0.016)。在调整贝克抑郁量表评分后,预测抗抑郁药使用的种族(非裔美国人与白人)优势比为0.43(95%置信区间0.24 - 0.76,P = 0.004)。
尽管患有相似程度的抑郁症,但与白人相比,患有冠心病的非裔美国人接受抗抑郁药物治疗的可能性较小。抑郁症心理药物治疗的种族差异表明,有必要更仔细地评估抑郁症,尤其是在非裔美国人中,以优化冠心病患者的护理。